title: How to select amongst available options for the treatment of advanced RCC?
abstract: The treatment of renal cell carcinoma has dramatically changed in the past 6 years with the approval of seven new drugs since 2006. although treatment algorithms have been reported and updated every year since 2006, the choice of targeted therapy is not always easy. Selecting a targeted agent in metastatic renal cell carcinoma (mRCC) should take into account various parameters, including the status of the disease, the histology, the status of the patient and finally the availability of the drugs in each country. In addition, in front of every patient, the physician will need to raise important questions such as whether the patient should be treated, should receive surgery, and also what is his prognostic group. The different options are described in this manuscript.
authors.affiliation: Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif 94800, France. escudier@igr.fr
authors.forename: B
authors.initials: B
authors.lastname: Escudier
authors.forename: L
authors.initials: L
authors.lastname: Albiges
authors.forename: C
authors.initials: C
authors.lastname: Massard
authors.forename: Y
authors.initials: Y
authors.lastname: Loriot
authors.forename: K
authors.initials: K
authors.lastname: Fizazi
mesh_terms: D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology*; D017326:Clinical Trials, Phase III as Topic; D018450:Disease Progression; D006801:Humans; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D012307:Risk Factors; D016019:Survival Analysis; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D047428:Protein Kinase Inhibitors; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases